secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0000950170-23-032300
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista FY2023 net loss $92.9M; sebetralstat Phase 3 enrollment complete
-------------------------------------------------------------------------

- Phase 3 KONFIDENT trial achieved target enrollment (114 patients); data readout expected Q4 2023; NDA planned H1 2024.
- Net loss FY2023 $92.9M ($3.33/share) vs $82.3M ($3.36/share); no revenue.
- R&D expenses $80.3M (FY2023) vs $70.2M; G&A $30.6M vs $26.4M.
- Cash, equivalents and marketable securities $149.4M; funded into 2025 after $58M registered direct offering.
- Promoted Benjamin Palleiko to President; appointed Brian Pereira as Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/0000950170-23-032300-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017023032300/kalv-20230707.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-032300

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer